CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating
web-based and internet-based applications/interventions, including mobile interventions,
electronic games (incl multiplayer games), social media, certain telehealth applications, and
other interactive and/or networked electronic applications. Some of the items (e.g. all
subitems under item 5 - description of the intervention) may also be applicable for other
study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published
in the Journal of Medical Internet Research and other journals / scientific societies
endorsing the checklist.

Items numbered 1., 2., 3., 4s., 4b etc are original CONSORT or CONSORT-NPT (non-
pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH
extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask
that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE
PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this
form - please include any quotes from your manuscript in QUOTATION MARKS,
or answer directly by providing additional information not in the manuscript, or elaborating
on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION
IN JMI AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use
proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS
ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the
caption):
Lysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and
Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829
* Required

Your name *
First Last
Puhong Zhang

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
The George Institute for Global Health, Beijing.

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmr... 10/03/2020
| **Your e-mail address** * |
|--------------------------|
| also@mail.com |
| zpuhong@georgeinstitute.org.cn |

| **Title of your manuscript** * |
|-----------------------------|
| Provide the (draft) title of your manuscript. |
| Road to Hierarchical Diabetes Management at Primary Care (ROADMAP) Study in China: Statistical Analysis Plan for a Cluster Randomized Controlled Trial |

| **Name of your App/Software/Intervention** * |
|---------------------------------------------|
| If there is a short and a long/alternate name, write the short name first and add the long name in brackets. |
| ROADMAP is the study name, Graded ROADMAP |

| **Evaluated Version (if any)** |
|-------------------------------|
| e.g. "V1", "Release 2017-03-01", "Version 2.0.27913" |
| Your answer |

| **Language(s)** * |
|-------------------|
| What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French") |
| Chinese |

| **URL of your Intervention Website or App** |
|---------------------------------------------|
| e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page. |
| Your answer |

| **URL of an image/screenshot (optional)** |
|------------------------------------------|
| Your answer |

| **Accessibility** * |
|---------------------|
| Can an enduser access the intervention presently? |
|   | access is free and open |
|   | access only for special usergroups, not open |
|   | access is open to everyone, but requires payment/subscription/in-app purchases |
|   | app/intervention no longer accessible |
|   | Other: |

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmr... 10/03/2020
Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimer (Informal Caregivers of)"
Diabetes (primary care service providers of)

Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial
HbA1c control rate

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?
HbA1c level, percentages of the attainments of BP and LDL-C and composite ABC targets

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?
- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *
- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71-80%
- 81-90%
- 91-100%
- Other:
Overall, was the app intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other: Unknown at this stage since the analysis has not began

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered
Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you log in as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other: JRP ms#18333

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
Is the title contain the phrase "Randomized Controlled Trial"? (If not, explain the reason under "other")

- yes
- Other:

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iPhone"), especially if the application runs on different platforms.

subitem not at all important  O  O  O  O  O  essential

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks 'like this') to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The item is not applicable for us, since "mobile-based" is only one aspect of the intervention, due to the word limit of the title, we presented the full name of the study which contains the population, setting and context, which we think would be more important for the readers.

1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

subitem not at all important  O  O  O  O  O  essential
Does your paper address subitem 1a-ii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 1a-iii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"diabetes management at primary care"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionality/components of the intervention and comparator in the METHODS section of the ABSTRACT
Mention key features/functionality/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexing by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"a tiered diabetes management model on diabetes control to usual care"

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT
Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any) (Note: Only report in the abstract and the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1b-iii) Open vs. closed, web-based (self-assessment) vs face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed web-based trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicate the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enroll). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussion in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem 1b-v?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-ij) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study, intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 2a-ij?

*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

*to determine the effectiveness of a strengthened version of before-mentioned essential public health service on diabetes management*

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e., what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 2a-ii?

*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The rationale has been fully explained in the previously published protocol paper which we have included as reference [3]

2b) In INTRODUCTION: Specific objectives or hypotheses
Does your paper address CONSORT subitem 2b? *
- Copy and paste relevant sections from the manuscript (include direct quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The purpose of this plan is to outline the pre-determined analytical methods in detail before completion of database lock to reduces potential bias and facilitate transparent analyses."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
- Copy and paste relevant sections from the manuscript (include direct quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Community-based, cluster randomized controlled", "with 2:1 ratio"

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *
- Copy and paste relevant sections from the manuscript (include direct quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not applicable/relevant for our study since no important change have been made.

3b-i) Bug fixes, Downtimes, Content Changes
Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-6) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 3b-i?
- Copy and paste relevant sections from the manuscript (include direct quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

4a) Eligibility criteria for participants
Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Participants are adult patients with established T2D who have registered for the essential public health service within community at the time of recruitment. To be eligible, participants should be 18-75 years old, reside in the community for the previous 6 months with no plan of relocating, and provide informed consent. Potential participants are excluded if they have severe physical or psychological injury/illness, and/or are unable to attend the site visit and/or consciously answer questions, and/or are women in the process of, or planning for, pregnancy or breastfeeding, and/or have participated in any other clinical trial within the previous 6 months." *

4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

subitem not at all important 〇 〇 〇 〇 〇  essential

Does your paper address subitem 4a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree the study team knew the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all important 〇 〇 〇 〇 〇  essential

Does your paper address subitem 4a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not described in detail in this MS, because it was introduced in the protocol paper. Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e031734.

4a-iii) Information giving during recruitment
Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

subitem not at all important 〇 〇 〇 〇 〇  essential
Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"from 864 communities/villages in 144 districts/counties in 25 provinces"

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not described in detail in this MS, because it was introduced in the protocol paper.
Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734.

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript.

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (end comparison, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer
5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

- subitem not at all important
- essential

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

- subitem not at all important
- essential

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

- subitem not at all important
- essential

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer
5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vii).

| subitem not at all important | ○ | ○ | ○ | ○ | ○ | essential |

Does your paper address subitem 5-vii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not described in detail in this MS, because it was introduced in the protocol paper. Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734. And the “backdoor” login account could be granted upon reasonable request with approval.

5-viii) Mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework
Describe mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework [1] used to design them (instructional strategies [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1],” whether (and how) it is tailored to individual circumstances and allows users to track their progress and receive feedback” [16]. This also includes a description of communication delivery channels, e.g. if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including usage design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

| subitem not at all important | ○ | ○ | ○ | ○ | ○ | essential |

Does your paper address subitem 5-viii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Besides a standard training workshop for the contracted service providers (community, township and county level doctors) in intervention arm, the key components of intervention were monthly-scheduled one BP measurement and two blood glucose monitoring tests (at least one fasting blood glucose [FBG]), instruction for lifestyle change and medication accordingly, timely referral if indicator presents, and quarterly performance review for the contracted service team. A mobile-health-based information system, Graded ROADMAP, was developed and employed to support the contracted doctor team delivering the intervention. Another smartphone application, Your Doctor, was available for participants in intervention arm to facilitate health education and communication between the designated doctors and patients. “ Further description is available in the protocol paper. Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734.

5-ix) Describe use parameters
Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heavy use of, if any, or was the intervention used ad libitum.

| subitem not at all important | ○ | ○ | ○ | ○ | ○ | essential |
### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

| subitem not at all important |   |   |   |   | essential |
|-----------------------------|---|---|---|---|-----------|

### 5-x) Report any prompts/reminders used

Report any prompts/reminders used. Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

| subitem not at all important |   |   |   |   | essential |
|-----------------------------|---|---|---|---|-----------|

### 5-x) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support). Clearly state any interventions that are provided in addition to the targeted ehealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

| subitem not at all important |   |   |   |   | essential |
|-----------------------------|---|---|---|---|-----------|

---

The glucose level will be colourfully labelled when app-embedded threshold reached. But it was not mentioned since this is a statistical methodology describing paper.
6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The primary outcome is HbA1c control rate (at target <7.0%, target A) at one year. That is, the percentage of patients achieving HbA1c<7.0 %. The secondary outcomes include percentage of patients achieving both SBP<140 mmHg and DBP<80 mmHg (target B); percentage of patients achieving LDL-C<2.6 mmol/L (target C) optimal control rate of combined ABC targets as defined above; percentage of patients achieving FPG<7.0 mmol/L; changes in levels of HbA1c, blood pressure, LDL-C, and FPG, and subtype-specific and overall hypoglycemia episodes [11]. Other outcomes are health-related quality of life measured by the EuroQol (EQ-5D-3L) questionnaire [11,12]; mean change in the scores of the summary of diabetes self-care activities questionnaire [13], development of any self-reported new-onset comorbidities and diabetic complications during follow-up, concomitant medications, and direct medical cost."

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deploeyed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and supply CHERRIES criteria to describe how the questionnaires were designed/deployed [6].

subitem not at all important 0 0 0 0 0 essential

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/ adoption metrics are important process outcomes that should be reported in any eHealth trial.

subitem not at all important 0 0 0 0 0 essential
Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

Your answer

6a-iii Describe whether, how, and when qualitative feedback from participants was obtained
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 6b-ii?
Copy and paste relevant sections from manuscript text

Your answer

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No change has been made.

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

7a-ii Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 7a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

7b) When applicable, explanation of any interim analyses and stopping guidelines
| Question                                                                 | Response |
|-------------------------------------------------------------------------|----------|
| Does your paper address CONSORT subitem 7b? *                         |          |
| Copy and paste relevant sections from the manuscript (include quotes in   |          |
| quotation marks "like this" to indicate direct quotes from your         |          |
| manuscript), or elaborate on this item by providing additional          |          |
| information not in the ms, or briefly explain why the item is not        |          |
| applicable/relevant for your study                                      |          |
| "No formal interim analysis will be performed. "                        |          |
| 8a) Method used to generate the random allocation sequence               |          |
| NPT: When applicable, how care providers were allocated to each trial   |          |
| group                                                                    |          |
| Does your paper address CONSORT subitem 8a? *                         |          |
| Copy and paste relevant sections from the manuscript (include quotes in   |          |
| quotation marks "like this" to indicate direct quotes from your         |          |
| manuscript), or elaborate on this item by providing additional          |          |
| information not in the ms, or briefly explain why the item is not        |          |
| applicable/relevant for your study                                      |          |
| "centrally randomized"                                                  |          |
| 8b) Type of randomisation: details of any restriction (such as blocking   |          |
| and block size)                                                         |          |
| Does your paper address CONSORT subitem 8b? *                         |          |
| Copy and paste relevant sections from the manuscript (include quotes in   |          |
| quotation marks "like this" to indicate direct quotes from your         |          |
| manuscript), or elaborate on this item by providing additional          |          |
| information not in the ms, or briefly explain why the item is not        |          |
| applicable/relevant for your study                                      |          |
| "cluster randomized" and "communities/villages (clusters) "            |          |
| 9) Mechanism used to implement the random allocation sequence (such as   |          |
| sequentially numbered containers), describing any steps taken to        |          |
| conceal the sequence until interventions were assigned                  |          |
| Does your paper address CONSORT subitem 9? *                          |          |
| Copy and paste relevant sections from the manuscript (include quotes in   |          |
| quotation marks "like this" to indicate direct quotes from your         |          |
| manuscript), or elaborate on this item by providing additional          |          |
| information not in the ms, or briefly explain why the item is not        |          |
| applicable/relevant for your study                                      |          |
| Detailed description is available in the protocol paper. Reference [8].    |          |
| Jia W, Zhang P, Duilikun N, Zhu D, Li H, Bao Y et al. Study protocol for  |          |
| the road to hierarchical diabetes management at primary care (ROADMAP)   |          |
| study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734. |          |
| 10) Who generated the random allocation sequence, who enrolled           |          |
| participants, and who assigned participants to interventions            |          |
| Does your paper address CONSORT subitem 10? *                         |          |
| Copy and paste relevant sections from the manuscript (include quotes in   |          |
| quotation marks "like this" to indicate direct quotes from your         |          |
| manuscript), or elaborate on this item by providing additional          |          |
| information not in the ms, or briefly explain why the item is not        |          |
| applicable/relevant for your study                                      |          |
| Detailed description is available in the protocol paper. Reference [8].    |          |
| Jia W, Zhang P, Duilikun N, Zhu D, Li H, Bao Y et al. Study protocol for  |          |
| the road to hierarchical diabetes management at primary care (ROADMAP)   |          |
| study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734. |          |
11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
NPT: Whether or not administering co-interventions were blinded to group assignment

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | 6 | Essential |
|-----------------------------|---|---|---|---|---|---|------------|
| Does your paper address subitem 11a-i? * |
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Detailed description is available in the protocol paper. Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734.

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | 6 | Essential |
|-----------------------------|---|---|---|---|---|---|------------|
| Does your paper address subitem 11a-ii? |
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for eHealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

| Does your paper address CONSORT subitem 11b? * |
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Detailed description is available in the protocol paper. Reference [8]. Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734.

12a) Statistical methods used to compare groups for primary and secondary outcomes
NPT: When applicable, details of whether and how the clustering by care providers or centers was taken into account


Does your paper address CONSORT subitem 12a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The whole methods sections elaborate this point.

12a-i) Imputation techniques to deal with attrition / missing values
Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in eHealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 12a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Imputation will be performed as sensitivity analysis when missing observations in HbA1c at 1 year exceed 10%. " Multiple imputation (MI) using fully conditional specification [16] will be performed as a sensitivity analysis when more than 10% of observations in HbA1c is missing at one year. The imputation model will include the levels of HbA1c, FBG, blood pressure, and LDL-C at one year and at baseline, a cluster indicator, a group indicator, and baseline variables including age, sex, education, duration of diabetes, medical history, comorbidities, concomitant medications, and resource utilization, etc. Ten sets of imputed data will be created and analyzed using the Model 1 (described in primary analyses). HbA1c, FBG, blood pressure, and LDL-C will first be imputed as continuous variables using linear regression and subsequently recategorized into binary variables."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Five pre-specified subgroup analyses will be carried out between the overall intervention group and the control group. They are economic development level (developed vs less-developed), locality (urban vs rural), age group (age>60 vs ≤60), duration of diabetes (≤6 vs >6 years, around the median), and diabetic complication (Yes vs No; Yes, defined as presence of any diagnosed diabetic nephropathy, diabetic retinopathy, peripheral neuropathy, carotid artery disease, lower extremity artery disease, diabetic foot damage, peripheral vascular disease, coronary stenosis, myocardial infarction, post coronary artery surgery, cerebral infarction, cerebral hemorrhage). The analysis for each subgroup analysis will be performed by adding the subgroup variable along with its interaction with the intervention as fixed effects to the primary model (Model 1). Within each subgroup, the raw counts and percentages within each treatment arm will be presented, as well as the relative risks and their 95% CIs for intervention effect from the primary model. The results will be displayed on a forest plot including the P-value for heterogeneity corresponding to the interaction term between the intervention and the subgroup variable."

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)
### X26-i) Comment on ethics committee approval

| subitem not at all important |   |   |   |   | essential |

**Does your paper address subitem X26-i?**
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

**Your answer**

### X26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkboxes, etc.), and what information was provided (see 4a-i). See [4] for some items to be included in informed consent documents.

| subitem not at all important |   |   |   |   | essential |

**Does your paper address subitem X26-ii?**
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

**Your answer**

### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline).

| subitem not at all important |   |   |   |   | essential |

**Does your paper address subitem X26-iii?**
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

**Your answer**

### RESULTS

#### 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

---

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvrm... 10/03/2020
Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"an average of 22" and "IT population"

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Detailed description is available in the protocol paper. Reference [8]. Jia W, Zhang P, Duulikun N, Zhu D, Li H, Bao Y, et al. Study protocol for the road to hierarchical diabetes management at primary care (ROADMAP) study in China: a cluster randomised controlled trial BMJ Open 2020;10(1):e032273.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

- Subitem not at all important
- Subitem not essential
- Subitem essential

Does your paper address subitem 13b-i? 

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Recruitment commenced in June 2017, and closed after completed baseline assessment in December 2018 for all 864 trial participating communities in 144 districts/counties in 25 provincial sites (one more province than the scheduled 24 because of the shortage in finding the enough eligible district/county hospital). As of October 2019, the last one-year end-of-study assessment ended."
14a-i) Indicate if critical "secular events" fell into the study period
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

| subitem not at all important | ☐ | ☐ | ☐ | ☐ | ☐ | essential |

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14b) Why the trial ended or was stopped (early).

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see "Table 1"

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/internet/ehealth literacy of the participants, if known.

| subitem not at all important | ☐ | ☐ | ☐ | ☐ | ☐ | essential |

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see "Table 1"

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
16-i) Report multiple "denominators" and provide definitions
Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation (and) thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

subitem not at all important □ □ □ □ □ essential

16-ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-ii).

subitem not at all important □ □ □ □ □ essential

Does your paper address subitem 16-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the text, or briefly explain why the item is not applicable/relevant for your study

Your answer

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the text, or briefly explain why the item is not applicable/relevant for your study

see "Table 2 and Table 3"

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (doses, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-i) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "location" is defined (e.g., time out after idle time) [2] (report under item 6a).

subitem not at all important □ □ □ □ □ essential
Does your paper address subitem 17a? *  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Analysis for binary categorical outcomes
A similar analytic strategy as for the primary outcome will be followed for other binary outcomes. These include the proportion of FPG <7.0 mmol/L, BP <140/80 mmHg, and that of LDL-C <2.6 mmol/L, and the optimal control rate of combined ABC targets. A log-binomial regression with GEE and including baseline continuous values of the analyzed outcome variable as covariate (Model 1) will be used. Other further adjusted analysis (Model 2) and subgroup analysis will also be conducted, and the imputed analysis as well if applicable."

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Five pre-specified subgroup analyses will be carried out between the overall intervention group and the control group."

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in eHealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-ii).

| subitem not at all important | | | | | essential |

Does your paper address subitem 18-i?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

*Analysis of hypoglycemia
Episodes of hypoglycemia (each subtype and overall) will be analyzed with the same approach as before; this time using Poisson regression adjusted for the baseline count of hypoglycemia.*

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on unwarranted interventions or the approach, especially if they point to unforeseen/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group
22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This article presents the detailed statistical analysis plan for the ROADMAP study, which is a cluster-randomized controlled trial conducted in diverse areas in China with the purpose of testing the effectiveness of an mHealth platform named Graded Roadmap on diabetes control."

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Although the economic development level (developed vs less-developed) and locality (urban vs rural) have been included in the predetermined sub-group analysis, more detailed descriptions might be needed for the factorial sub-groups."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discus biases due to non-use of the intervention/withdrawal issues, biases through informed consent procedures, unexpected events.

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"No adjustment will be applied for multiplicity, given that most of the effectiveness outcomes are correlated or consist in different versions of common variables."

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmr... 10/03/2020
21) Generalisability (external validity, applicability) of the trial findings
NPT: External validity of the trial findings according to the interventions, comparisons, patients, and care providers or centers involved in the trial

21-i) Generalisability to other populations
Generalisability to other populations: In particular, discuss generalisability to a general internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 21-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks 'like this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting
Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 21-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks 'like this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks 'like this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Trial Registration: Chinese Clinical Trial Registry (ChiCTR-IOR-17011325)." *

24) Where the full trial protocol can be accessed, if available
Does your paper address CONSORT subitem 247? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Protocol is available: Jia W, Zhang P, Duolikun N, Zhu D, Li H, Bao Y et al. Study protocol for the road to hierarchical diabetes management at primary care (3DADMAP) study in China: a cluster randomised controlled trial. BMJ Open. 2020;10(1):e032734.

Source of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 257? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"This study received its principle funding from Dongbao Pharmaceutical Co., Ltd. through Bethune Charitable Foundation. Dongbao Pharmaceutical Co., Ltd. also provided in-kind support including decision-making system, blood glucose monitoring equipment (smart blood glucose meters) and consumables to facilitate the implementation of intervention. Wuxi BioHermes Bio&Medical Technology Co., Ltd provided point-of-care HbA1c analyzers (A1c E2.0) for universal testing of HbA1c. All the funders did not participate in the study design, implementation, data analysis and interpretation of the results."

X27) Conflicts of Interest (not a CONSORT Item)

X27-1) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

Submit item not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem X27-1?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

○ yes, major changes
○ yes, minor changes
○ no
What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript?

3 hours

As a result of using this checklist, do you think your manuscript has improved?

- yes
- no
- Other:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document.

- yes
- no
- Other:

Any other comments or questions on CONSORT EHEALTH

I prefer checklist with check-box instead of copy-pasting the whole text.

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMRI, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!
